Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Javier Nieves-Costas

Gastroenterology Tampa, FL Medical Doctor

NPI 1780812297 CMS profile 1352123

4301 N Habana Ave, Tampa, FL 33607

Open in the dashboard

General payments

$8,990

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Javier Nieves-Costas of Tampa, FL is reported in the CMS Open Payments database as having received $8,990 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,398 46
2024 General $1,607 40
2023 General $1,618 39
2022 General $795 21
2021 General $795 30
2020 General $521 36
2019 General $1,257 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javier Nieves-Costas
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Javier Nieves-Costas were reported at $2,398. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Javier Nieves-Costas Gastroenterology median Middle half National median
2019 $1,257 $417 $126–$1,100 $163
2020 $521 $224 $74–$624 $114
2021 $795 $352 $106–$1,054 $132
2022 $795 $448 $129–$1,270 $149
2023 $1,618 $533 $150–$1,390 $160
2024 $1,607 $605 $160–$1,606 $164
2025 $2,398 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,066 137 payments
  2. Penumbra, Inc. $769 6 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $675 40 payments
  4. Janssen Biotech, Inc. $540 11 payments
  5. Boston Scientific Corporation $411 6 payments
  6. Genzyme Corporation $410 8 payments
  7. Janssen Scientific Affairs, LLC $357 3 payments
  8. Phathom Pharmaceuticals, Inc. $271 3 payments
  9. Medtronic, Inc. $237 2 payments
  10. Gilead Sciences, Inc. $234 6 payments
  11. Other $2,019 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,963 277 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. CREON $1,141 78 payments
  2. STELARA $754 12 payments
  3. RED 72 $717 5 payments
  4. LINZESS $682 38 payments
  5. XIFAXAN $545 37 payments
  6. RINVOQ $515 22 payments
  7. SKYRIZI Immunology $508 18 payments
  8. DUPIXENT $410 8 payments
  9. SKYRIZI Immunology $332 10 payments
  10. TREMFYA $289 3 payments
  11. Other $3,612 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

312

Median for Gastroenterology: 569

Drug cost

$30,335

Median for Gastroenterology: $104,976

Branded share of claims

14.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 18 $16,402
Dexlansoprazole Dr Dexlansoprazole Brand 16 $6,117
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 12 $2,031
Sucralfate Generic 25 $1,858
Famotidine Generic 50 $1,025
Omeprazole Generic 71 $962
Pantoprazole Sodium Generic 92 $952
Dicyclomine Hcl Generic 13 $663
Lansoprazole Generic 15 $325

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$44,340

Medicare's payments for the services billed

Medicare patients

225

Average age 73

Services billed

434

126 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 56%
Chronic kidney disease 51%
Ischemic heart disease 47%
Depression 40%
Heart failure 35%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $230
$230 — —
CREON
  • AbbVie, Inc. $165
$165 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $114
$114 — —
STELARA
  • Janssen Biotech, Inc. $112
$112 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record